Inventor · disambiguated record
Martin K. Safo
Also filed as: SAFO MARTIN · SAFO MARTIN K
30 granted patents·7 pending applications·133 citations·filing 1994–2024
96Inventor score
Files withUNIV KING ABDULAZIZ18UNIV VIRGINIA COMMONWEALTH14SAFO MARTIN2ALLOS THERAPEUTICS INC1INNOVATIVE TECH CENTER1
Top patents by PatentIndex Score
37 records- 0197US10836729B1Metabolically stable 5-HMF derivatives for the treatment of hypoxiaUNIV KING ABDULAZIZ·Filed 2020·Granted Nov 17, 2020·4 cites·4 claims
- 0294US10836736B1Pharmaceutical composition with cytotoxic activity on colorectal cancer cellsUNIV KING ABDULAZIZ·Filed 2020·Granted Nov 17, 2020·7 cites·3 claims
- 0392US11325885B2Method for treating stomach cancerUNIV KING ABDULAZIZ·Filed 2021·Granted May 10, 2022·1 cites·2 claims
- 0491US11214537B2Method for making anti-cancer compoundsUNIV KING ABDULAZIZ·Filed 2021·Granted Jan 4, 2022·1 cites·4 claims
- 0590US11319292B2Metabolically stable 5-HMF derivatives for the treatment of hypoxiaUNIV KING ABDULAZIZ·Filed 2021·Granted May 3, 2022·1 cites·4 claims
- 0690US11136288B2Method for treating a patient having cancerUNIV KING ABDULAZIZ·Filed 2021·Granted Oct 5, 2021·1 cites·7 claims
- 0789US11312680B2Method for treating a patient having a colon cancerUNIV KING ABDULAZIZ·Filed 2021·Granted Apr 26, 2022·1 cites·2 claims
- 0889US11142493B1Pharmaceutical composition for treating cancerUNIV KING ABDULAZIZ·Filed 2021·Granted Oct 12, 2021·1 cites·3 claims
- 0989US7160910B2Anti-sickling agentsXECHEM INTERNATIONAL INC·Filed 2003·Granted Jan 9, 2007·63 cites·6 claims
- 1086US7119208B2Anti-sickling agentsUNIV VIRGINIA COMMONWEALTH·Filed 2005·Granted Oct 10, 2006·5 cites·13 claims
- 1184US10709662B1Mucoadhesive buccal film having a dual release carrier systemUNIV KING ABDULAZIZ·Filed 2020·Granted Jul 14, 2020·2 cites·9 claims
- 1283US11104632B1Metabolically stable vanillin derivatives for the treatment of hypoxiaUNIV KING ABDULAZIZ·Filed 2020·Granted Aug 31, 2021·1 cites·4 claims
- 1383US10653634B1Polymeric nanoparticulate formulation to enhance the oral bioavailability of dapoxetineUNIV KING ABDULAZIZ·Filed 2019·Granted May 19, 2020·2 cites·13 claims
- 1480US10988439B2Cytotoxic compounds, pharmaceutical compositions thereof, and methods of treating cancerUNIV KING ABDULAZIZ·Filed 2019·Granted Apr 27, 2021·1 cites·6 claims
- 1580US6486342B1Substituted chiral allosteric hemoglobin modifiersUNIV VIRGINIA COMMONWEALTH·Filed 2000·Granted Nov 26, 2002·13 cites·16 claims
- 1679US12065408B2Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2023·Granted Aug 20, 2024·0 cites·11 claims
- 1779US5599974AAldehydic agents for allosteric modification of hemoglobinINNOVATIVE TECH CENTER·Filed 1994·Granted Feb 4, 1997·18 cites·28 claims
- 1878US10344001B2Azolylacryloyl derivatives as therapeutic agents for sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2016·Granted Jul 9, 2019·3 cites·2 claims
- 1977US10875834B2Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivativesUNIV VIRGINIA COMMONWEALTH·Filed 2017·Granted Dec 29, 2020·2 cites·4 claims
- 2077US9765017B2Allosteric hemoglobin modifiers with nitric oxide releasing moietyUNIV VIRGINIA COMMONWEALTH·Filed 2014·Granted Sep 19, 2017·4 cites·9 claims
- 2174US11214556B1Method of treating colorectal cancerUNIV KING ABDULAZIZ·Filed 2021·Granted Jan 4, 2022·0 cites·2 claims
- 2274US10844007B1Amide group-containing compounds and use for cancer treatmentUNIV KING ABDULAZIZ·Filed 2020·Granted Nov 24, 2020·0 cites·9 claims
- 2374US2025019349A1Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2024·Application pending·0 cites
- 2473US11312694B2Method for making propenamide compoundUNIV KING ABDULAZIZ·Filed 2021·Granted Apr 26, 2022·0 cites·2 claims
- 2569US11155528B2Bis-propenamide compounds and methods of treating cancerUNIV KING ABDULAZIZ·Filed 2019·Granted Oct 26, 2021·0 cites·2 claims
- 2668US11149012B1Metabolically stable 5-HMF derivatives for the treatment of hypoxiaUNIV KING ABDULAZIZ·Filed 2020·Granted Oct 19, 2021·0 cites·2 claims
- 2764US10800751B2Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2014·Granted Oct 13, 2020·0 cites·5 claims
- 2864US6894185B2Substituted chiral allosteric hemoglobin modifiersALLOS THERAPEUTICS INC·Filed 2002·Granted May 17, 2005·2 cites·5 claims
- 2963US10858331B1Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Dec 8, 2020·0 cites·2 claims
- 3061US2022340531A1Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2022·Application pending·0 cites
- 3161US2024109843A1Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2023·Application pending·0 cites
- 3259US2021053931A1Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 3355US2005154062A1Substituted chiral allosteric hemoglobin modifiersUNIV VIRGINIA COMMONWEALTH·Filed 2004·Application pending·0 cites
- 3453US11458144B1Methods for using 5-HMF analogs with increased solubility to inhibit or reverse RBC sicklingUNIV KING ABDULAZIZ·Filed 2021·Granted Oct 4, 2022·0 cites·4 claims
- 3551US11401241B2Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell diseaseUNIV VIRGINIA COMMONWEALTH·Filed 2019·Granted Aug 2, 2022·0 cites·10 claims
- 3648US2013266668A1Use of hemoglobin effectors to increase the bioavailability of therapeutic gasesSAFO MARTIN·Filed 2011·Application pending·0 cites
- 3748US2017326086A1Use of hemoglobin effectors to increase the bioavailability of therapeutic gasesSAFO MARTIN·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Martin K. Safo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →